Skip to main content
Top
Published in: BMC Cancer 1/2010

Open Access 01-12-2010 | Research article

Combined effects of cigarette smoking, gene polymorphisms and methylations of tumor suppressor genes on non small cell lung cancer: a hospital-based case-control study in China

Authors: Yongtang Jin, Heyun Xu, Chunye zhang, Yunming Kong, Yong Hou, Yingchun Xu, Shaoli Xue

Published in: BMC Cancer | Issue 1/2010

Login to get access

Abstract

Background

Cigarette smoking is the most established risk factor, and genetic variants and/or gene promoter methylations are also considered to play an essential role in development of lung cancer, but the pathogenesis of lung cancer is still unclear.

Methods

We collected the data of 150 cases and 150 age-matched and sex-matched controls on a Hospital-Based Case-Control Study in China. Face to face interviews were conducted using a standardized questionnaire. Gene polymorphism and methylation status were measured by RFLP-PCR and MSP, respectively. Logistic regressive model was used to estimate the odds ratios (OR) for different levels of exposure.

Results

After adjusted age and other potential confounding factors, smoking was still main risk factor and significantly increased 3.70-fold greater risk of NSCLC as compared with nonsmokers, and the ORs across increasing levels of pack years were 1, 3.54, 3.65 and 7.76, which the general dose-response trend was confirmed. Our striking findings were that the risk increased 5.16, 8.28 and 4.10-fold, respectively, for NSCLC with promoter hypermethylation of the p16, DAPK or RARβ gene in smokers with CYP1A1 variants, and the higher risk significantly increased in smokers with null GSTM1 and the OR was 17.84 for NSCLC with p16 promoter hypermethylation, 17.41 for DAPK, and 8.18 for RARβ in smokers with null GSTM1 compared with controls (all p < 0.01).

Conclusion

Our study suggests the strong combined effects of cigarette smoke, CYP1A1 and GSTM1 Polymorphisms, hypermethylations of p16, DAPK and RARβ promoters in NSCLC, implying complex pathogenesis of NSCLC should be given top priority in future research.
Literature
1.
go back to reference Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA: Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008, 83: 584-594. 10.4065/83.5.584.CrossRefPubMedPubMedCentral Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA: Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008, 83: 584-594. 10.4065/83.5.584.CrossRefPubMedPubMedCentral
2.
go back to reference Herbst RS, Heymach JV, Lippman SM: Lung cancer. N Engl J Med. 2008, 359: 1367-1380. 10.1056/NEJMra0802714.CrossRefPubMed Herbst RS, Heymach JV, Lippman SM: Lung cancer. N Engl J Med. 2008, 359: 1367-1380. 10.1056/NEJMra0802714.CrossRefPubMed
3.
go back to reference Lee kM, Kang D, Clapper ML, Ingelman-Sundberg M, Ono-Kihara M, Kiyohara C, et al: CYP1A1, GSTM1, and GSTT1 polymorphisms, smoking, and lung cancer risk in a pooled analysis among Asian populations. Cancer Epidemiol Biomarkers Prev. 2008, 17: 1120-1126. 10.1158/1055-9965.EPI-07-2786.CrossRefPubMed Lee kM, Kang D, Clapper ML, Ingelman-Sundberg M, Ono-Kihara M, Kiyohara C, et al: CYP1A1, GSTM1, and GSTT1 polymorphisms, smoking, and lung cancer risk in a pooled analysis among Asian populations. Cancer Epidemiol Biomarkers Prev. 2008, 17: 1120-1126. 10.1158/1055-9965.EPI-07-2786.CrossRefPubMed
4.
go back to reference Risch A, Plass C: Lung cancer epigenetics and genetics. Int J Cancer. 2008, 123: 1-7. 10.1002/ijc.23605.CrossRefPubMed Risch A, Plass C: Lung cancer epigenetics and genetics. Int J Cancer. 2008, 123: 1-7. 10.1002/ijc.23605.CrossRefPubMed
5.
go back to reference Bartsch H, Nair U, Risch A, Rojas m, Wikman H, Alexandrov K: Genetic polymorphism of CYP gene, alone or in combination, as a risk modifier of tobacco-related cancers. Cancer Epidemiol. Biomarkers Prev. 2000, 9: 3-28. Bartsch H, Nair U, Risch A, Rojas m, Wikman H, Alexandrov K: Genetic polymorphism of CYP gene, alone or in combination, as a risk modifier of tobacco-related cancers. Cancer Epidemiol. Biomarkers Prev. 2000, 9: 3-28.
6.
go back to reference Schwartz AG, Prysak GM, Bock CH, Cote ML: The molecular epidemiology of lung cancer. Carcinogenesis. 2007, 28: 507-518. 10.1093/carcin/bgl253.CrossRefPubMed Schwartz AG, Prysak GM, Bock CH, Cote ML: The molecular epidemiology of lung cancer. Carcinogenesis. 2007, 28: 507-518. 10.1093/carcin/bgl253.CrossRefPubMed
7.
go back to reference Hecht SS: Cigarette smoking and lung cancer: chemical mechanisms and approaches to prevention. Lancet Oncol. 2002, 3: 461-469. 10.1016/S1470-2045(02)00815-X.CrossRefPubMed Hecht SS: Cigarette smoking and lung cancer: chemical mechanisms and approaches to prevention. Lancet Oncol. 2002, 3: 461-469. 10.1016/S1470-2045(02)00815-X.CrossRefPubMed
8.
go back to reference Adonis M, Martinez V, Marin P, Gil L: CYP1A1 and GSTM1 genetic polymorphisms in lung cancer populations exposed to arsenic in drinking water. Xenobiotica. 2005, 35: 519-530. 10.1080/00498250500057310.CrossRefPubMed Adonis M, Martinez V, Marin P, Gil L: CYP1A1 and GSTM1 genetic polymorphisms in lung cancer populations exposed to arsenic in drinking water. Xenobiotica. 2005, 35: 519-530. 10.1080/00498250500057310.CrossRefPubMed
9.
go back to reference Shi X, Zhou S, Wang Z, Zhou Z, Wang Z: CYP1A1 and GSTM1 polymorphisms and lung cancer risk in Chinese populations: A meta-analysis. Lung Cancer. 2008, 59: 155-163. 10.1016/j.lungcan.2007.08.004.CrossRefPubMed Shi X, Zhou S, Wang Z, Zhou Z, Wang Z: CYP1A1 and GSTM1 polymorphisms and lung cancer risk in Chinese populations: A meta-analysis. Lung Cancer. 2008, 59: 155-163. 10.1016/j.lungcan.2007.08.004.CrossRefPubMed
10.
go back to reference Belinsky SA, Klinge DM, Dekker JD, Smith MW, Bocklage TJ, Gilliland FD, et al: Gene promoter methylation in plasma and sputum increases with lung cancer risk. Clin Cancer Res. 2005, 11: 6505-6511. 10.1158/1078-0432.CCR-05-0625.CrossRefPubMed Belinsky SA, Klinge DM, Dekker JD, Smith MW, Bocklage TJ, Gilliland FD, et al: Gene promoter methylation in plasma and sputum increases with lung cancer risk. Clin Cancer Res. 2005, 11: 6505-6511. 10.1158/1078-0432.CCR-05-0625.CrossRefPubMed
11.
go back to reference Fujiwara K, Fujimoto N, Tabata M, Nishii K, Matsuo K, Hotta K, et al: Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer. Clin Cancer Res. 2005, 11: 1219-1225. 10.1158/1078-0432.CCR-04-2363.CrossRefPubMed Fujiwara K, Fujimoto N, Tabata M, Nishii K, Matsuo K, Hotta K, et al: Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer. Clin Cancer Res. 2005, 11: 1219-1225. 10.1158/1078-0432.CCR-04-2363.CrossRefPubMed
12.
go back to reference Zochbauer-Muller S, Fong KM, Virmani AK, Geradts J, Gazdar AF, Minna JD: Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Research. 2001, 61: 249-255.PubMed Zochbauer-Muller S, Fong KM, Virmani AK, Geradts J, Gazdar AF, Minna JD: Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Research. 2001, 61: 249-255.PubMed
14.
go back to reference Yoshino I, Maehara Y: Impact of smoking status on the biological behavior of lung cancer. Surg Today. 2007, 37: 725-734. 10.1007/s00595-007-3516-6.CrossRefPubMed Yoshino I, Maehara Y: Impact of smoking status on the biological behavior of lung cancer. Surg Today. 2007, 37: 725-734. 10.1007/s00595-007-3516-6.CrossRefPubMed
15.
go back to reference Cornfield J, Haenszel W, Hammond EC, Lilienfeld AM, Shimkin MB, Wynder EL: Smoking and lung cancer: recent evidence and a discussion of some questions. Intern J Epidemiol. 2009, 38: 1175-1191. 10.1093/ije/dyp289.CrossRef Cornfield J, Haenszel W, Hammond EC, Lilienfeld AM, Shimkin MB, Wynder EL: Smoking and lung cancer: recent evidence and a discussion of some questions. Intern J Epidemiol. 2009, 38: 1175-1191. 10.1093/ije/dyp289.CrossRef
16.
go back to reference Doll R, Peto R: Mortality in relation to smoking: 20 year's observations on male British doctors. Br Med J. 1976, 2: 1525-1536. 10.1136/bmj.2.6051.1525.CrossRefPubMedPubMedCentral Doll R, Peto R: Mortality in relation to smoking: 20 year's observations on male British doctors. Br Med J. 1976, 2: 1525-1536. 10.1136/bmj.2.6051.1525.CrossRefPubMedPubMedCentral
17.
18.
go back to reference Kawajiri K, Nakachi K, Imai K, Yoshii A, Shinoda N, Watanabe J: Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P4501A1 gene. FEBS Lett. 1990, 263: 131-133. 10.1016/0014-5793(90)80721-T.CrossRefPubMed Kawajiri K, Nakachi K, Imai K, Yoshii A, Shinoda N, Watanabe J: Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P4501A1 gene. FEBS Lett. 1990, 263: 131-133. 10.1016/0014-5793(90)80721-T.CrossRefPubMed
19.
go back to reference Vineis P, Veglia F, Benhamou S, Butkiewicz D, Cascorbi I, Clapper ML, et al: CYP1A1 T3801 C polymorphism and lung cancer: a pooled analysis of 2451 cases and 3358 controls. Int J Cancer. 2003, 104: 650-657. 10.1002/ijc.10995.CrossRefPubMed Vineis P, Veglia F, Benhamou S, Butkiewicz D, Cascorbi I, Clapper ML, et al: CYP1A1 T3801 C polymorphism and lung cancer: a pooled analysis of 2451 cases and 3358 controls. Int J Cancer. 2003, 104: 650-657. 10.1002/ijc.10995.CrossRefPubMed
20.
go back to reference Houlston RS: Glutathione S-transferase M1 status and lung cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Pre. 1999, 8: 675-682. Houlston RS: Glutathione S-transferase M1 status and lung cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Pre. 1999, 8: 675-682.
21.
go back to reference Vineis P, Veglia F, Anttila S, Benhamou S, Clapper ML, Dolzan V, et al: CYP1A1, GSTM1 and GSTT1 polymorphisms and lung cancer: a pooled analysis of gene-gene interactions. Biomarkers. 2004, 9: 298-305. 10.1080/13547500400011070.CrossRefPubMed Vineis P, Veglia F, Anttila S, Benhamou S, Clapper ML, Dolzan V, et al: CYP1A1, GSTM1 and GSTT1 polymorphisms and lung cancer: a pooled analysis of gene-gene interactions. Biomarkers. 2004, 9: 298-305. 10.1080/13547500400011070.CrossRefPubMed
22.
go back to reference Vineis P, Anttila S, Benhamou S, Spinola M, Hirvonen A, Kiyohara C, et al: Evidence of gene gene interactions in lung carcinogenesis in a large pooled analysis. Carcinogenesis. 2007, 28: 1902-1905. 10.1093/carcin/bgm039.CrossRefPubMed Vineis P, Anttila S, Benhamou S, Spinola M, Hirvonen A, Kiyohara C, et al: Evidence of gene gene interactions in lung carcinogenesis in a large pooled analysis. Carcinogenesis. 2007, 28: 1902-1905. 10.1093/carcin/bgm039.CrossRefPubMed
23.
go back to reference Benhamou S, Lee WJ, Alexandrie AK, Boffetta P, Bouchardy C, Butkiewicz D, et al: Meta- and pooled analysis of the effects of glutathione S-transferase M1 polymorphisms and smoking on lung cancer risk. Carcinogenesis. 2002, 23: 1343-1350. 10.1093/carcin/23.8.1343.CrossRefPubMed Benhamou S, Lee WJ, Alexandrie AK, Boffetta P, Bouchardy C, Butkiewicz D, et al: Meta- and pooled analysis of the effects of glutathione S-transferase M1 polymorphisms and smoking on lung cancer risk. Carcinogenesis. 2002, 23: 1343-1350. 10.1093/carcin/23.8.1343.CrossRefPubMed
24.
go back to reference Butkiewicz D, Cole KJ, Phillips DH, Harris CC, Chorazy M: GSTM1, GSTP1, CYP1A1 and CYP2D6 polymorphisms in lung cancer patients from an environmentally polluted region of Poland: correlation with lung DNA adduct levels. Eur J Cancer Prev. 1999, 8: 315-323. 10.1097/00008469-199908000-00008.CrossRefPubMed Butkiewicz D, Cole KJ, Phillips DH, Harris CC, Chorazy M: GSTM1, GSTP1, CYP1A1 and CYP2D6 polymorphisms in lung cancer patients from an environmentally polluted region of Poland: correlation with lung DNA adduct levels. Eur J Cancer Prev. 1999, 8: 315-323. 10.1097/00008469-199908000-00008.CrossRefPubMed
25.
go back to reference Belinsky SA: Silencing of genes by promoter hypermethylation: key event in rodent and human lung cancer. Carcinogenesis. 2005, 26: 1481-1487. 10.1093/carcin/bgi020.CrossRefPubMed Belinsky SA: Silencing of genes by promoter hypermethylation: key event in rodent and human lung cancer. Carcinogenesis. 2005, 26: 1481-1487. 10.1093/carcin/bgi020.CrossRefPubMed
26.
go back to reference Zöchbauer-Müller S, Minna JD, Gazdar AF: Aberrant DNA methylation in lung cancer: biological and clinical implications. Oncologist. 2002, 7: 451-457. 10.1634/theoncologist.7-5-451.CrossRefPubMed Zöchbauer-Müller S, Minna JD, Gazdar AF: Aberrant DNA methylation in lung cancer: biological and clinical implications. Oncologist. 2002, 7: 451-457. 10.1634/theoncologist.7-5-451.CrossRefPubMed
27.
go back to reference Safar AM, Spencer H, Su X, Coffey M, Cooney CA, Ratnasinghe LD, et al: Methylation profiling of archived non-small cell lung cancer: a promising prognostic system. Clin Cancer Res. 2005, 11: 4400-4405. 10.1158/1078-0432.CCR-04-2378.CrossRefPubMed Safar AM, Spencer H, Su X, Coffey M, Cooney CA, Ratnasinghe LD, et al: Methylation profiling of archived non-small cell lung cancer: a promising prognostic system. Clin Cancer Res. 2005, 11: 4400-4405. 10.1158/1078-0432.CCR-04-2378.CrossRefPubMed
28.
go back to reference Chan EC, Lam SY, Fu KH, Kwong YL: Polymorphisms of the GSTM1, GSTP1 MPO, XRCC1, and NQO1 genes in Chinese patients with non-small cell lung cancers: relationchip with aberrant promoter methylation of the CDKN2A and RARβ genes. Cancer Genet Cytogenet. 2005, 162: 10-20. 10.1016/j.cancergencyto.2005.03.008.CrossRefPubMed Chan EC, Lam SY, Fu KH, Kwong YL: Polymorphisms of the GSTM1, GSTP1 MPO, XRCC1, and NQO1 genes in Chinese patients with non-small cell lung cancers: relationchip with aberrant promoter methylation of the CDKN2A and RARβ genes. Cancer Genet Cytogenet. 2005, 162: 10-20. 10.1016/j.cancergencyto.2005.03.008.CrossRefPubMed
Metadata
Title
Combined effects of cigarette smoking, gene polymorphisms and methylations of tumor suppressor genes on non small cell lung cancer: a hospital-based case-control study in China
Authors
Yongtang Jin
Heyun Xu
Chunye zhang
Yunming Kong
Yong Hou
Yingchun Xu
Shaoli Xue
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2010
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-10-422

Other articles of this Issue 1/2010

BMC Cancer 1/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine